Literature DB >> 18045938

Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor.

H Jacques Garrigues1, Yelena E Rubinchikova, C Michael Dipersio, Timothy M Rose.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) envelope-associated glycoprotein B (gB) is involved in the initial steps of binding to host cells during KSHV infection. gB contains an RGD motif reported to bind the integrin alpha(3)beta(1) during virus entry. Although the ligand specificity of alpha(3)beta(1) has been controversial, current literature indicates that alpha(3)beta(1) ligand recognition is independent of RGD. We compared alpha(3)beta(1) to the RGD-binding integrin, alpha(V)beta(3), for binding to envelope-associated gB and a gB(RGD) peptide. Adhesion assays demonstrated that beta(3)-CHO cells overexpressing alpha(V)beta(3) specifically bound gB(RGD), whereas alpha(3)-CHO cells overexpressing alpha(3)beta(1) did not. Function-blocking antibodies to alpha(V)beta(3) inhibited the adhesion of HT1080 fibrosarcoma cells to gB(RGD), while antibodies to alpha(3)beta(1) did not. Using affinity-purified integrins and confocal microscopy, alpha(V)beta(3) bound to gB(RGD) and KSHV virions, demonstrating direct receptor-ligand interactions. Specific alpha(V)beta(3) antagonists, including cyclic and dicyclic RGD peptides and alpha(V)beta(3) function-blocking antibodies, inhibited KSHV infection by 70 to 80%. Keratinocytes from alpha(3)-null mice lacking alpha(3)beta(1) were fully competent for infection by KSHV, and reconstitution of alpha(3)beta(1) function by transfection with alpha(3) cDNA reduced KSHV infectivity from 74% to 55%. Additional inhibitory effects of alpha(3)beta(1) on the cell surface expression of alpha(V)beta(3) and on alpha(V)beta(3)-mediated adhesion of alpha(3)-CHO cells overexpressing alpha(3)beta(1) were detected, consistent with previous reports of transdominant inhibition of alpha(V)beta(3) function by alpha(3)beta(1). These observations may explain previous reports of an inhibition of KSHV infection by soluble alpha(3)beta(1). Our studies demonstrate that alpha(V)beta(3) is a cellular receptor mediating both the cell adhesion and entry of KSHV into target cells through binding the virion-associated gB(RGD).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045938      PMCID: PMC2224453          DOI: 10.1128/JVI.01673-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.

Authors:  W Xue; I Mizukami; R F Todd; H R Petty
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Epiligrin, a new cell adhesion ligand for integrin alpha 3 beta 1 in epithelial basement membranes.

Authors:  W G Carter; M C Ryan; P J Gahr
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

3.  Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor.

Authors:  J P Kim; K Zhang; R H Kramer; T J Schall; D T Woodley
Journal:  J Invest Dermatol       Date:  1992-05       Impact factor: 8.551

4.  Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor.

Authors:  J W Smith; D A Cheresh
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

5.  Changing ligand specificities of alphavbeta1 and alphavbeta3 integrins by swapping a short diverse sequence of the beta subunit.

Authors:  J Takagi; T Kamata; J Meredith; W Puzon-McLaughlin; Y Takada
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

Review 6.  The alpha v beta 3 integrin "vitronectin receptor".

Authors:  M A Horton
Journal:  Int J Biochem Cell Biol       Date:  1997-05       Impact factor: 5.085

Review 7.  Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton.

Authors:  K Burridge; K Fath; T Kelly; G Nuckolls; C Turner
Journal:  Annu Rev Cell Biol       Date:  1988

8.  The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit.

Authors:  J W Smith; D A Cheresh
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

9.  Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.

Authors:  R Renne; D Blackbourn; D Whitby; J Levy; D Ganem
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

10.  A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus.

Authors:  R C Desrosiers; V G Sasseville; S C Czajak; X Zhang; K G Mansfield; A Kaur; R P Johnson; A A Lackner; J U Jung
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

View more
  67 in total

1.  c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells.

Authors:  Sayan Chakraborty; Mohanan ValiyaVeettil; Sathish Sadagopan; Nitika Paudel; Bala Chandran
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.

Authors:  Alexander S Hahn; Johanna K Kaufmann; Effi Wies; Elisabeth Naschberger; Julia Panteleev-Ivlev; Katharina Schmidt; Angela Holzer; Martin Schmidt; Jin Chen; Simone König; Armin Ensser; Jinjong Myoung; Norbert H Brockmeyer; Michael Stürzl; Bernhard Fleckenstein; Frank Neipel
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

3.  Integrin-targeting block copolymer probes for two-photon fluorescence bioimaging.

Authors:  Sanchita Biswas; Xuhua Wang; Alma R Morales; Hyo-Yang Ahn; Kevin D Belfield
Journal:  Biomacromolecules       Date:  2010-12-29       Impact factor: 6.988

4.  Cell membrane-bound Kaposi's sarcoma-associated herpesvirus-encoded glycoprotein B promotes virus latency by regulating expression of cellular Egr-1.

Authors:  Ossie F Dyson; Christopher M Traylen; Shaw M Akula
Journal:  J Biol Chem       Date:  2010-09-23       Impact factor: 5.157

5.  Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin.

Authors:  Li-Wu Qian; Whitney Greene; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus glycoproteins B and K8.1 regulate virion egress and synthesis of vascular endothelial growth factor and viral interleukin-6 in BCBL-1 cells.

Authors:  R Subramanian; I Sehgal; O D'Auvergne; K G Kousoulas
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells.

Authors:  Feng-Chun Ye; Fu-Chun Zhou; Stanley Nithianantham; Bala Chandran; Xiao-Lan Yu; Aaron Weinberg; Shou-Jiang Gao
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

9.  Kaposi's sarcoma-associated herpesvirus forms a multimolecular complex of integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during infection of human dermal microvascular endothelial cells, and CD98-xCT is essential for the postentry stage of infection.

Authors:  Mohanan Valiya Veettil; Sathish Sadagopan; Neelam Sharma-Walia; Fu-Zhang Wang; Hari Raghu; Laszlo Varga; Bala Chandran
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Viral adaptation to host: a proteome-based analysis of codon usage and amino acid preferences.

Authors:  Iris Bahir; Menachem Fromer; Yosef Prat; Michal Linial
Journal:  Mol Syst Biol       Date:  2009-10-13       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.